Avenue Therapeutics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Alix MacLean

Chief Executive Officer (CEO)

US$1.2m

Compensación total

Porcentaje del salario del CEO	33.0%
Permanencia del CEO	2.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Alix MacLean en comparación con los beneficios de Avenue Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$9m
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$1m	US$400k	-US$10m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$516k	US$154k	-US$4m

Compensación vs. Mercado: La compensación total de Alix($USD1.21M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).

Compensación vs. Ingresos: La compensación de Alix ha aumentado mientras la empresa no es rentable.

CEO

Alix MacLean (57 yo)

2.3yrs

Permanencia

US$1,213,200

Compensación

Dr. Alexandra MacLean, also known as Alix, MD, serves as Director of Kent Imaging Inc. since January 2021. She is Chief Executive Officer at Avenue Therapeutics, Inc. since August 01, 2022 and serves as it...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexandra MacLean	CEO & Director	2.3yrs	US$1.21m	sin datos
David Jin	Interim CFO	2.7yrs	US$260.00k	sin datos
Lindsay Rosenwald	Executive Director	1.7yrs	US$104.00k	0.33% $ 9.4k
Scott Reines	Interim Chief Medical Officer	8.8yrs	US$123.12k	sin datos

2.5yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ATXI se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexandra MacLean	CEO & Director	1.7yrs	US$1.21m	sin datos
Lindsay Rosenwald	Executive Director	9.8yrs	US$104.00k	0.33% $ 9.4k
Jay Kranzler	Chairman of the Board	7.8yrs	US$212.19k	0.039% $ 1.1k
Neil Herskowitz	Non-Executive Independent Director	9.3yrs	US$164.00k	0.0084% $ 241.1
Faith Charles	Independent Director	2.5yrs	US$154.00k	sin datos
Curtis Oltmans	Independent Director	3.6yrs	US$154.00k	0.0031% $ 88.3

5.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de ATXI se considera experimentada (5.7 años de antigüedad promedio).

Avenue Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Recent updates

New major risk - Financial position

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad